Business Wire

Helfie AI Appoints Healthcare Industry Leaders Antonin de Fougerolles and Cheryl Buxton to the Board of Directors

Share

Helfie AI, aglobal mobile health platform, has appointed two new members to its Board of Directors. Renowned international scientist Antonin (Tony) de Fougerolles, PhD, will hold the position of non-executive chairman, and global healthcare executive Cheryl Buxton will be an independent non-executive board member.

Helfie AI is a ground-breaking mobile platform powered by artificial intelligence that enables anyone with a smartphone anywhere in the world to check for a range of health conditions quickly and accurately. These appointments herald a pivotal phase in Helfie AI's mission to revolutionise global healthcare access and participation.

George Tomeski, Helfie AI co-founder and CEO said: “The addition to the Board of healthcare experts of Tony’s and Cheryl’s calibre is an important stage in the company’s development. Helfie will put basic, lifesaving health checks literally in the hands of billions of people around the world. As we move to commercialise our revolutionary technology, we are excited to be able to attract Tony and Cheryl, who have such a wealth of healthcare experience and deep experience in early stage companies.”

Dr. de Fougerolles was the founding chief scientific officer of Moderna and most recently the CEO of Evox Therapeutics. Over a 25-year career in drug development, he helped create three transformative drug platforms resulting in multiple approved drugs in areas including infectious disease, cardiology, and rare disease. He also helped grow several start-ups into multi-billion-dollar enterprises. Dr. de Fougerolles brings a wealth of expertise in how to operationally scale companies and will advise Helfie AI on company building, fundraising, and selection of health conditions best suited for Helfie’s technology.

Ms. Buxton’s most recent role was vice chairman, Pharmaceuticals and R&D at Korn Ferry International, the global organisational consulting firm. She brings a vast knowledge of the healthcare industry across a wide variety of sectors and geographies. Ms. Buxton has in-depth global experience building high performing teams for many of the world’s top healthcare companies and will help Helfie to grow into a multi-national organisation and to link with leaders across the healthcare industry.

​Dr.de Fougerolles said: “Helfie AI is the first company I’ve seen that has the potential to revolutionalise medical care by making health checks easy and accessible to everyone – similar to what Apple did for music. The ability to identify and check for health concerns early will lead to better outcomes for patients. I’m excited to turn my time and attention to working with the Helfie team on this transformational platform.”

Ms. Buxton said: “Helfie AI holds the promise of redressing the imbalance of healthcare access by people of different socio-economic backgrounds in different regions around the world. Everyone from a single mother in a remote area to a time-poor executive in a large city can have access to basic checks through Helfie’s technology. The potential to bring a genuinely equitable approach to preventative healthcare is extremely attractive to me as I join the board.”

Helfie AI's advanced AI technologies analyse pictures, videos, sound recordings or face scans to check for indications of potential health conditions. Helfie AI generates instant results and offers the user information and options on what to do next. Importantly, the user owns and controls all of the data provided as part of the checks.

About Helfie AI

Helfie AI was founded in Melbourne, Australia in 2021 and has expanded operations to Europe, North America, Africa and Asia with multiple active B2B partnerships with top tier companies already in place.

Helfie AI tackles two of healthcare’s most fundamental challenges: the lack of participation in preventative healthcare and the under-utilisation of health data. Every facet of healthcare, starting with the quality and longevity of human life, can be dramatically improved if everyone actively participates in preventative health and if health data is actively utilized throughout the healthcare system.

The accessibility made possible by Helfie AI can significantly reduce the $7 trillion spent annually on treating preventable conditions.

Helfie AI provides users with clear next steps, connects them to medical care if/as required, allows interaction around numerous health conditions, from cardiovascular to skin health, and enables sharing AI findings with their own carers and doctors.

More details on the checks Helfie can make are available at www.helfie.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241017104893/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Textron Aviation Unveils Exclusive EvoX Upgrades: Comprehensive and Factory-Direct Modification Packages for Cessna Citation and Beechcraft King Air Customers17.10.2024 17:00:00 CEST | Press release

Textron Aviation today announced the launch of “EvoX,” specialized aftermarket upgrade packages designed for Cessna Citation and Beechcraft King Air customers who are seeking the latest aircraft upgrades and modifications to maximize the value of their aircraft. EvoX allows customers to bundle state-of-the-art avionics, cutting-edge connectivity solutions, exclusive luxurious interior refurbishments and sleek exterior upgrades into one easy to schedule and complete comprehensive modification package. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241014724767/en/ Textron Aviation announced the launch of “EvoX,” specialized aftermarket upgrade packages designed for Cessna Citation and Beechcraft King Air customers who are seeking the latest aircraft upgrades and modifications to maximize the value of their aircraft. (Textron Aviation) Beechcraft and Cessna customers receive factory-direct support, maintenance and modification

LTIMindtree Delivers 2.8% QoQ USD Revenue Growth17.10.2024 16:03:00 CEST | Press release

Growth across all Verticals, EBIT Margin improves to 15.5%Adds 2,500+ employees in Q2 LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced its consolidated results today for the second quarter ended Sep. 30, 2024, as approved by its Board of Directors. "Q2 was a good quarter marked by broad-based sequential growth experienced across all our verticals and geos, helping us register a dollar growth of 2.8%. We had several multi-year deal closures, including a USD 200 million+ deal. Continued deal momentum in key verticals and significant Q2 hiring, including freshers, positions us well as we enter into the latter half of the fiscal year. "As GenAI becomes pivotal in customer interactions, there is a noticeable trend of modernization efforts focusing on transforming the data estate. Our robust Data practice, combined with our innovative LTIMindtree AI platform, establishes us as a significant disruptor." - Debashis Chatterjee, Chief

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 202417.10.2024 15:00:00 CEST | Press release

Nordic Pharma to share this innovation and its pivotal study article in the Journal of Cataract and Refractive Surgery (JCRS) with ophthalmology leaders Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. in April and will continue its introduction to leading ophthalmologists during AAO 2024. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system. LACRIFILL Canalicular Gel allows patient’s eyes to be bathed by their own natural tears. It is customized for each individual patient and provides a full fill of the canalicular system. LACRIFILL Canalicular Gel is administered through a simple in-office procedure, which is reimbursed through an existing CPT code (68761). The results last for six months. “We are delighted to be representing Nordic Pharma at AAO,” said Phil Gioia, President of the U.S. t

DriveWealth Bolsters Connectivity for Institutional Broker-Dealers, Enhancing Global Reach and Operational Efficiency17.10.2024 15:00:00 CEST | Press release

Expanded EMS integrations and telecom support will reduce integration times for BDs and enhance trading capabilities and market access DriveWealth, a leading financial technology platform providing Brokerage-as-a-Service, today announced its end-to-end integration with multiple execution management system (EMS) platforms, including Bloomberg EMSX, LSEG Autex and TRAFiX. With these integrations, institutional broker-dealers can connect with DriveWealth’s platform and benefit from streamlined trade booking, reduced integration times, and seamless access to advanced features. “Our goal is to make it turnkey for any institutional broker-dealer to connect to DriveWealth’s existing technology stack without modifying existing systems or infrastructure,” said Aaron Sokasian, Chief Technology Officer at DriveWealth. “With improved connectivity, brokerage firms can experience superior execution quality and extended trading capabilities at a competitive price, all while utilizing the platforms th

Westlake Global Compounds Sites Receive Silver Medal from EcoVadis17.10.2024 15:00:00 CEST | Press release

Westlake Corporation (NYSE: WLK) today announced that Westlake Global Compounds businesses and operating sites outside of the U.S. - Westlake Compounds Holdings, S.A.S. - have been awarded the esteemed EcoVadis Silver Medal, reflecting the company’s commitment to improved environmental sustainability and corporate social responsibility. This accolade places these Westlake Global Compounds sites among the top 15% of companies assessed by EcoVadis globally over the past year. EcoVadis is the world’s largest and most trusted provider of business sustainability ratings and evaluates companies globally on their corporate social responsibility performance using international standards like the Global Reporting Initiative, the United Nations Global Compact, and ISO 26000. “Receiving the EcoVadis Silver Medal is a significant milestone for Westlake Global Compounds and underscores our commitment to environmental stewardship and ethical business practices,” said Bridget Confait-Smith, associate

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye